LAG3 anticorps (Extracellular Domain)
Aperçu rapide pour LAG3 anticorps (Extracellular Domain) (ABIN6992262)
Antigène
Voir toutes LAG3 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- Extracellular Domain
-
Purification
- LAG-3 Antibody is supplied as protein A purified IgG2a.
-
Immunogène
- LAG-3 antibody was raised against the extracellular domain of human LAG-3
-
Isotype
- IgG2a kappa
-
-
-
-
Indications d'application
-
LAG-3 antibody can be used for ELISA starting at 0.25 μ,g/mL. For Immunocytochemistry start at 1 μ,g/mL. For Immunofluorescence start at 10 μ,g/mL. For Immunohistochemistry start at 5 μ,g/mL. For Flow Cytometry start at 1 μ,g/mL.
Antibody validated: Immunohistochemistry in human samples, Immunocytochemistry in human samples, Immunofluorescence in human samples and Flow Cytometry in human samples. All other applications and species not yet tested. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- LAG-3 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C,4 °C
-
Stockage commentaire
- LAG-3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Autre désignation
- LAG3
-
Sujet
- The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1), negatively regulating T-cell function and homeostasis (2). It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3), and acts to regulate T cell expansion (4). LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy.
-
ID gène
- 3902
-
NCBI Accession
- NP_002277
-
UniProt
- P18627
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Antigène
-